Takeda Caught Surprised By Outcomes For Two Key Products
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Takeda Pharmaceuticals' highly positive Phase III data for antibody drug conjugate SGN-35 (brentuximab vedotin) - partnered with Seattle Genetics - is a bright spot for the company after a "complete response" letter to partner Orexigen for obesity drug Contrave (bupropion/naltrexone)